<DOC>
	<DOCNO>NCT00573430</DOCNO>
	<brief_summary>To determine effective dose candesartan cilexetil reduction urinary protein excretion hypertensive patient non-diabetic chronic kidney disease baseline urinary protein/creatinine ratio 500mg/g 5000mg/g , assess change urinary protein/creatinine ratio baseline end 28-week treatment</brief_summary>
	<brief_title>ARIA ( Atacand Renoprotection In NephropAthy Pt . )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>hypertension ; ) 135mmHg &lt; Systolic Blood Pressure &lt; 180mmHg and/or 85 mmHg &lt; Diastolic Blood Pressure &lt; 100 mmHg . b ) The subject treat antihypertensive medication proteinuria ( urinary protein/creatinine ratio 500 mg/g 5000 mg/g ) Current serumcreatinine &gt; 265 mmol/L ( &gt; 3 mg/dL ) . Current serumpotassium &gt; 5.5 mmol/L Known hypersensitivity angiotensin ( AT ) 1receptor blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Candesartan Cilexetil</keyword>
	<keyword>Non-diabetic Nephropathy</keyword>
	<keyword>hypertension</keyword>
	<keyword>urine protein creatinine ratio</keyword>
</DOC>